Predict your next investment

Debt & Specialty Finance
FINANCE | Asset/Financial Management
htgc.com

See what CB Insights has to offer

Investments

199

Portfolio Exits

62

Funds

2

Partners & Customers

2

About Hercules Capital

Hercules Capital (NYSE:HTGC) ("Hercules") is a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy & renewable technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.6 billion to over 300 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.

Hercules Capital Headquarter Location

400 Hamilton Avenue Suite 310

Palo Alto, California, 94301,

United States

650-289-3060

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Hercules Capital Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Hercules Capital Rank

Latest Hercules Capital News

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 4, 2022

San Francisco, California, UNITED STATES SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2022 and provided business updates. “During the second quarter of this year we took important steps toward optimizing our capital structure to support the ongoing development of efruxifermin (EFX) by closing a $25 million equity investment from Pfizer and a $100 million term loan facility from Hercules Capital,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “We look forward to reporting Week 24 results of our ongoing Phase 2b HARMONY study in patients with pre-cirrhotic NASH in September of this year, consistent with prior guidance.” Second Quarter Business Highlights Akero announced a $25 million equity investment from Pfizer Inc. and up to a $100 million term loan facility through Hercules Capital, Inc., to support continued development of EFX, Akero’s lead product candidate. Akero presented an analysis at the 2022 International Liver Congress demonstrating the potential for EFX to treat patients at the highest genetic risk for progressive NASH and end-stage liver disease, including hepatocellular carcinoma. Data showed that EFX improved histopathology and noninvasive markers of liver injury to a similar extent in patients carrying the highest risk PNPLA3 genotype as patients who were not carriers. Akero presented a new post hoc analyses of the BALANCED study at the 2022 Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies, which highlighted how treatment with EFX was associated with a coordinated reduction in synthesis of 4 different collagen subtypes implicated in liver fibrosis. The reduction in synthesis of one of these subtypes, collagen III, was sufficient to normalize levels of the marker pro-C3 in 30% of EFX-treated compared to 0% of placebo patients. In addition, the proportion of collagen area in biopsy samples from cirrhotic NASH patients, quantitated by digital pathology, tended to be lower in EFX -treated than placebo patients. HARMONY Update All required visits for the Week 24 primary analysis in the ongoing Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3 fibrosis) NASH have been completed. Akero expects to report HARMONY results for the Week 24 primary endpoint (change from baseline in liver fibrosis with no worsening of steatohepatitis) and multiple secondary endpoints—including histology, noninvasive markers of liver injury, lipoproteins, measures of glycemic control, liver fat, body weight, and safety/tolerability—in September. SYMMETRY Update Based on enrollment to date, Akero expects to report results from the ongoing Phase 2b SYMMETRY main study in patients with cirrhosis due to NASH in the second half of 2023. In July, the first patient was randomized into Cohort D, an expansion cohort of the Phase 2b SYMMETRY study that will evaluate the safety and tolerability of EFX compared to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 Diabetes Mellitus. Second Quarter 2022 Financial Results Akero's cash, cash equivalents and short-term marketable securities for the period ended June 30, 2022 were $180.7 million. On June 15, 2022, Akero secured a $25 million equity investment from Pfizer, Inc. and an up to $100 million term loan facility from Hercules Capital, Inc., of which (i) $10.0 million was drawn at closing, (ii) an incremental $10.0 million is available to Akero at its sole discretion, (iii) $35 million will become available upon the achievement of certain clinical development and financial milestones, and (iv) $45.0 million will become available at Hercules’ sole discretion. Akero believes that its cash, cash equivalents and marketable securities, plus cash from the Hercules facility (if fully drawn), will be sufficient to fund its current operating plan until the third quarter of 2024. Research and development expenses for the three-month period ended June 30, 2022 were $21.4 million, compared to $24.0 million for the comparable period in 2021. These changes are mainly attributable to timing of completion of certain EFX manufacturing activities, including third-party contract manufacturing of Phase 3 drug product, contract research organization costs associated with the HARMONY and SYMMETRY studies, and internal personnel costs. General and administrative expenses for the three-month period ended June 30, 2022 were $6.2 million, compared to $5.0 million for the comparable period in 2021. These increases are attributable to higher expenses for personnel, including non-cash stock-based compensation, and professional services and other costs associated with operating as a public company. Total operating expenses were $27.6 million for the three-month period ended June 30, 2022, compared to $29.0 million for the comparable period in 2021. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero’s business plans and objectives, including future plans or expectations for efruxifermin (EFX), upcoming milestones, and therapeutic effects of EFX, including expected timing to report results of Akero’s Phase 2b HARMONY and SYMMETRY studies; and expectations regarding Akero’s use of capital, expenses and other future financial results, including the potential benefits and impact of the equity investment by Pfizer Inc. and the loan facility with Hercules Capital, Inc., and the potential impact of COVID-19 on strategy, future operations, manufacturing, and clinical trial enrollment and data collection. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of COVID-19 on Akero’s ongoing and future operations, including potential negative impacts on Akero’s employees, third-parties, manufacturers, supply chain and production as well as on global economies and financial markets; the success, cost, and timing of Akero’s product candidate development activities and planned clinical trials; Akero’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Akero Therapeutics, Inc.

Hercules Capital Investments

199 Investments

Hercules Capital has made 199 investments. Their latest investment was in Convoy as part of their Debt on April 4, 2022.

CBI Logo

Hercules Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/21/2022

Debt

Convoy

$100M

Yes

2

2/14/2022

Series A - III

Esme Learning Solutions

$15M

Yes

4

12/17/2021

Series C

NorthSea Therapeutics

$80M

Yes

18

12/6/2021

Debt

Subscribe to see more

$99M

Subscribe to see more

10

10/19/2021

Line of Credit

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/21/2022

2/14/2022

12/17/2021

12/6/2021

10/19/2021

Round

Debt

Series A - III

Series C

Debt

Line of Credit

Company

Convoy

Esme Learning Solutions

NorthSea Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$100M

$15M

$80M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

18

10

10

Hercules Capital Portfolio Exits

62 Portfolio Exits

Hercules Capital has 62 portfolio exits. Their latest portfolio exit was ZeroFox on August 04, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/4/2022

Reverse Merger

$99M

4

10/29/2021

Reverse Merger

$99M

3

6/15/2021

Reverse Merger

$99M

8

4/28/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/12/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/4/2022

10/29/2021

6/15/2021

4/28/2021

4/12/2021

Exit

Reverse Merger

Reverse Merger

Reverse Merger

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

3

8

10

10

Hercules Capital Acquisitions

3 Acquisitions

Hercules Capital acquired 3 companies. Their latest acquisition was Gibraltar Business Capital on March 05, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/5/2018

Debt

$99M

$250M

Acquired

2

3/10/2008

Subscribe to see more

$99M

Subscribe to see more

0

10/10/2007

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

3/5/2018

3/10/2008

10/10/2007

Investment Stage

Debt

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$250M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

0

0

Hercules Capital Fund History

2 Fund Histories

Hercules Capital has 2 funds, including Hercules Technology II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2007

Hercules Technology II

Expansions & Growth

Closed

$124M

1

12/31/2003

Hercules Technology Growth Capital

Subscribe to see more

Subscribe to see more

10

Closing Date

12/31/2007

12/31/2003

Fund

Hercules Technology II

Hercules Technology Growth Capital

Fund Type

Expansions & Growth

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$124M

Sources

1

10

Hercules Capital Partners & Customers

2 Partners and customers

Hercules Capital has 2 strategic partners and customers. Hercules Capital recently partnered with Tricida on March 3, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

3/2/2018

Partner

United States

Tricida Announces $100 Million Venture Debt Financing From Hercules Capital

`` Hercules Capital , Inc. is pleased to enter into this financing partnership with Tricida , Inc. at this important stage as it continues to advance its lead investigational drug candidate targeting patients with a significant unmet medical need , '' said Scott Bluestein , chief investment officer of Hercules Capital , Inc. .

2

6/12/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

3/2/2018

6/12/2017

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

Tricida Announces $100 Million Venture Debt Financing From Hercules Capital

`` Hercules Capital , Inc. is pleased to enter into this financing partnership with Tricida , Inc. at this important stage as it continues to advance its lead investigational drug candidate targeting patients with a significant unmet medical need , '' said Scott Bluestein , chief investment officer of Hercules Capital , Inc. .

Subscribe to see more

Subscribe to see more

Sources

2

10

Hercules Capital Team

27 Team Members

Hercules Capital has 27 team members, including current Chief Executive Officer, Chief Investment Officer, Scott Bluestein.

Name

Work History

Title

Status

Sarbvir Singh

Founder

Current

Scott Bluestein

Chief Executive Officer, Chief Investment Officer

Current

David Lund

Rainmaker Systems

Chief Financial Officer

Current

Seth Meyer

Chief Financial Officer

Current

Kristen Kosofsky

Managing Director

Current

Name

Sarbvir Singh

Scott Bluestein

David Lund

Seth Meyer

Kristen Kosofsky

Work History

Rainmaker Systems

Title

Founder

Chief Executive Officer, Chief Investment Officer

Chief Financial Officer

Chief Financial Officer

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.